In the news

TRImaran licenses WSU compounds to develop neuro drugs

February 11, 2016


TRImaran Pharma aims to take on a group of neurological diseases, like depression, by developing drugs that impact three different types of neurotransmitters in the brain. Those drug prospects come from Wayne State University, which licensed a group of molecules to the company this week for an undisclosed sum. Aloke Dutta, a pharmaceutical sciences professor at WSU and the head of the company’s scientific advisory board, led the research on the experimental drugs, which are known as “triple reuptake inhibitors,” because they simultaneously target three key neurotransmitters—serotonin, norepinephrine and dopamine—in the brain. TRImaran aims to use these drugs to treat neurological diseases from depression to ADHD and post-traumatic stress disorder.